Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVALUATION OF THE SAFETY AND THE CLINICAL PERFORMANCE IN TREATMENT OF CHRONIC DIABETIC FOOT ULCER, WITH THE TROPOCELLS®, BASED AUTOLOGOUS PLATELET RICH FIBRIN (Tropocells(R) Autologous PRF Systems)

NCT06810726 is registered in ClinicalTrials.gov with Estar Medical dba Medical Technologies, LTD as lead sponsor.

NCT NCT06810726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06810726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVALUATION OF THE SAFETY AND THE CLINICAL PERFORMANCE IN TREATMENT OF CHRONIC DIABETIC FOOT ULCER, WITH THE TROPOCELLS®, BASED AUTOLOGOUS PLATELET RICH FIBRIN (Tropocells(R) Autologous PRF Systems)
Lead sponsor
Estar Medical dba Medical Technologies, LTD
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2025
Completion date
August 15, 2026
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic wound care, chronic wound of the lower limb (leg ulcer or foot ulcer), diabetic foot ulcer, neuroischemic foot ulcer, type 1 diabetes mellitus, type 2 diabetes mellitus (t2dm)